Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3+CD4+CD25+ T regulatory cells in vivo and enhances their capacity to suppress EAE

European Journal of Immunology

Volumn 36, Issue 8, 2006, Pages 2139-2149

  Chen, Xin ^a   Oppenheim, Joost J ^b   Winkler Pickett, Robin T ^b   Ortaldo, John R ^b   Howard, O M Zack ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CD+CD25+ T regulatory cells; Dexamethasone; Experimental autoimmune encephalomyelitis; IL 2

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 2; MESSENGER RNA; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; TRANSCRIPTION FACTOR FOXP3;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG DOSE REGIMEN; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE ACTIVATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DEXAMETHASONE; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLUCOCORTICOIDS; INTERLEUKIN-2; MICE; RECEPTORS, INTERLEUKIN-2;

EID: 33747414436     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200635873     Document Type: Article

References (44)

1. Sakaguchi, S., Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000. 101: 455-458.
2. Sakaguchi, S., Naturally arising Foxp3-expressing CD25(+)CD4(+) regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 2005. 6: 345-352.
3. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M. and Toda, M., Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995. 155: 1151-1164.
4. Taylor, P. A., Noelle, R. J. and Blazar, B. R., CD4(+)CD25(+) immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 2001. 193: 1311-1318.
5. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 1998. 160: 1212-1218.
6. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001. 194: 823-832.
7. Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R. and Edinger, M., Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004. 104: 895-903.
8. Godfrey, W. R., Ge, Y. G., Spoden, D. J., Levine, B. L., June, C. H., Blazar, B. R. and Porter, S. B., In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004. 104: 453-461.
9. - precursors. J. Immunol. 2002. 169: 4183-4189.
10. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 2003. 198: 1875-1886.
11. - T cells. Int. Immunol. 2004. 16: 1203-1213.
12. Nelson, B. H., IL-2, regulatory T cells, and tolerance. J. Immunol. 2004. 172: 3983-3988.
13. Malek, T. R. and Bayer, A. L., Tolerance, not immunity, crucially depends on IL-2. Nat. Rev. Immunol. 2004. 4: 665-674.
14. Dutcher, J., Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma. Oncology (Huntingt) 2002. 16: 4-10.
15. Pahwa, S. and Morales, M., Interleukin-2 therapy in HIV infection. AIDS Patient Care STDS 1998. 12: 187-197.
16. Bianchi, M., Meng, C. and Ivashkiv, L. B., Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc. Natl. Acad. Sci. USA 2000. 97: 9573-9578.
17. Redondo, J. M., Fresno, M. and Lopez-Rivas, A., Inhibition of interleukin 2-induced proliferation of cloned murine T cells by glucocorticoids. Possible involvement of an inhibitory protein. Eur. J. Immunol. 1988. 18: 1555-1559.
18. - T cells to dexamethasone-induced cell death. Eur. J. Immunol. 2004. 34: 859-869.
19. Karagiannidis, C., Akdis, M., Holopainen, P., Woolley, N. J., Hense, G., Ruckert, B., Mantel, P. Y. et al., Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J. Allergy Clin. Immunol. 2004. 114: 1425-1433.
20. Hori, S., Nomura, T. and Sakaguchi, S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003. 299: 1057-1061.
21. + regulatory T cells. Nat. Immunol. 2003. 4: 330-336.
22. Wood, K. J. and Sakaguchi, S., Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 2003. 3: 199-210.
23. + regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis. J. Immunol. 2002. 169: 4712-4716.
24. + regulatory T cells. Int. Immunol. 2004. 16: 249-256.
25. + T lymphocytes. Blood 2005. 105: 2090-2092.
26. + T regulatory cells. Eur. J. Immunol. 2006. 36: 671-680.
27. Brunmark, C., Runstrom, A., Ohlsson, L., Sparre, B., Brodin, T., Astrom, M. and Hedlund, G., The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2002. 130: 163-172.
28. Schimpl, A. and Wecker, E., Replacement of T-cell function by a T-cell product. Nat. New. Biol. 1972. 237: 15-17.
29. Davey, R. T., Jr., Murphy, R. L., Graziano, F. M., Boswell, S. L., Pavia, A. T., Cancio, M., Nadler, J. P. et al., Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. Jama 2000. 284: 183-189.
30. Kovacs, J. A., Vogel, S., Albert, J. M., Falloon, J., Davey, R. T., Jr., Walker, R. E., Polis, M. A. et al., Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 1996. 335: 1350-1356.
31. Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A. et al., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003. 21: 3127-3132.
32. Atkins, M. B., Interleukin-2: clinical applications. Semin. Oncol. 2002. 29: 12-17.
33. Malek, T. R., Yu, A., Vincek, V., Scibelli, P. and Kong, L., CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002. 17: 167-178.
34. Papiernik, M., de Moraes, M. L., Pontoux, C., Vasseur, F. and Penit, C., Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int. Immunol. 1998. 10: 371-378.
35. + T cell numbers. J. Immunol. 2002. 169: 4850-4860.
36. Setoguchi, R., Hori, S., Takahashi, T. and Sakaguchi, S., Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 2005. 201: 723-735.
37. Bayer, A. L., Yu, A., Adeegbe, D. and Malek, T. R., Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J. Exp. Med. 2005. 201: 769-777.
38. Furtado, G. C., Curotto de Lafaille, M. A., Kutchukhidze, N. and Lafaille, J. J., Interleukin 2 signaling is required for CD4(+) regulatory T cell function. J. Exp. Med. 2002. 196: 851-857.
39. + T cell suppressor function. J. Immunol. 2004. 172: 6519-6523.
40. + regulatory T cells suppress effector T cell proliferation. Clin. Immunol. 2005. 115: 3-9.
41. Lesniak, M. S., Gabikian, P., Tyler, B. M., Pardoll, D. M. and Brem, H., Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors. J. Neurooncol. 2004. 70: 23-28.
42. Tavel, J. A., Sereti, I., Walker, R. E., Hahn, B., Kovacs, J. A., Jagannatha, S., Davey, R. T. et al., A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus. J. Infect. Dis. 2003. 188: 531-536.
43. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J. and Wiltrout, R. H., Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst. 1996. 88: 38-43.
44. Zhang, X., Izikson, L., Liu, L. and Weiner, H. L., Activation of CD25(+)CD4(+) regulatory T cells by oral antigen administration. J. Immunol. 2001. 167: 4245-4253.